Actionable news
All posts from Actionable news
Actionable news in FLXN: FLEXION THERAPEUTICS Inc,

Cytel Congratulates Flexion Therapeutics on Release of Phase 3 Data for Zilretta

CAMBRIDGE, Mass., May 05, 2016 (BUSINESS WIRE) -- Cytel Inc., a global provider of clinical research services and software, congratulates its client Flexion Therapeutics, Inc. on the release of Phase 3 data for its lead drug candidate Zilretta (also known as FX006). It was announced in February that the Phase 3 clinical trial met its primary endpoint at week 12, demonstrating highly significant (p<0.0001), durable and clinically meaningful pain relief against placebo in patients with moderate to severe osteoarthritis (OA) knee pain.

Cytel delivered statistical design, analysis and reporting services for the...